Medical Litigation News and Research

RSS

Fitch Ratings revises Merck & Co.'s outlook

Fitch Ratings has affirmed Merck & Co.'s (Merck) ratings, and revised the Rating Outlook to Negative from Stable.

18 Nov 2008

Spherix starts patient recruitment in India for phase 3 diabetes trial

Spherix Incorporated reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial.

8 Nov 2008

Education, health care expected to be among Obama's priorities

Guthrie is professor of Public Policy and Education; director, Peabody Center for Education Policy; and chair, Department of Leadership, Policy and Organizations at Vanderbilt's Peabody College.

8 Nov 2008

Mylan receives final approval for generic version of antiepileptic Keppra

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 250 mg, 500 mg and 750 mg. Levetiracetam Tablets are the generic version of UCB Pharma's Keppra.

4 Nov 2008

CytoDyn files new IND for Cytolin

CytoDyn, Inc. has filed a new IND for a study to reconfirm dose ranging and to "prove the principle" with a randomized, double-blind placebo controlled study of Cytolin, the Company's first-in-class drug for treating HIV/AIDS. This comes 13 years after the first IND was issued for the drug.

22 Oct 2008

Bayer's new oral anticoagulant Xarelto (Rivaroxaban) gets European licence

A new drug launched today could help in the fight against what experts and campaigners are calling a 'major patient safety issue' - the prevention of hospital-acquired DVT (deep vein thrombosis).

2 Oct 2008

Mylan's Alphapharm victorious in Razadyne patent challenge

Mylan Inc. has announced that its subsidiary Alphapharm Pty Limited won a favorable decision in patent litigation against it and Barr Laboratories Inc. relating to Galantamine Tablets, USP, the generic version of Ortho-McNeil's Razadyne Tablets, 4 mg, 8 mg and 12 mg.

31 Aug 2008

Meda settles U.S. Astelin patent litigation with Cobalt

Meda, through its wholly owned U.S. subsidiary, Meda Pharmaceuticals Inc., has entered into a settlement agreement with Cobalt Pharmaceuticals Inc. (hereafter Cobalt) that resolves the U.S. patent litigation between the companies regarding Cobalt's proposed generic version of Astelin.

25 Aug 2008

Barr Labs to settle Mirapex and Aggrenox patent challenges

Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.

12 Aug 2008

Wyeth and Impax settle Effexor XR patent case

Wyeth and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's Effexor XR antidepressant have been approved by the United States District Court for the District of Delaware.

17 Jul 2008

UnitedHealth Group announces lower profit outlook

UnitedHealth Group on Wednesday lowered its earnings guidance because of reduced commercial businesses and higher-than-expected Medicare-related costs and said it would restructure the company with a greater focus on regional coverage, the Chicago Tribune reports (Chicago Tribune, 7/3).

4 Jul 2008

Barr announces favorable ruling in Mirapex patent challenge

Barr Pharmaceuticals, Inc. has announced that U.S. District Court for Delaware has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Boehringer Ingelheim Pharmaceuticals, Inc. in connection with Boehringer Ingelheim's Mirapex(R) Tablets (pramipexole dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.

26 Jun 2008

Ranbaxy receives tentative approval to manufacture Valganciclovir hydrochloride tablets

Ranbaxy Laboratories Limited (RLL), announced today that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valganciclovir Hydrochloride Tablets, 450 mg. Total annual market sales for Valganciclovir HCl Tablets were $239 million (IMS - MAT: March 2008).

25 Jun 2008

Ranbaxy and Pfizer settle on Lipitor patent litigation

Ranbaxy Laboratories Limited (Ranbaxy), announced today that it has entered into an agreement with Pfizer Inc. to settle most of the patent litigation worldwide involving Atorvastatin (Lipitor), the world's most-prescribed cholesterol-lowering medicine.

19 Jun 2008

Mylan wins generic Prilosec patent litigation

Mylan Inc. has announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a May 2007 District Court ruling stating that Mylan's 10 mg and 20 mg Omeprazole delayed-release capsules do not infringe patents asserted against Mylan by AstraZeneca.

11 Jun 2008

Walgreen agrees to pay $35 million to settle allegations of improper medication switches for Medicaid beneficiaries

Walgreen has agreed to pay $35 million to settle allegations that the company improperly switched the form of generic medications prescribed to Medicaid beneficiaries to receive higher reimbursements from the program, the Hartford Courant reports (Levick, Hartford Courant, 6/5).

8 Jun 2008

Brand-name prescription drug companies reached 14 deals with generic manufacturers to delay sale of generics in FY 2007

Brand-name prescription drug makers in fiscal year 2007 reached 14 agreements with generic drug makers to delay market entry of generic medications, according to a report released on Wednesday by the Federal Trade Commission, Reuters reports (Bartz, Reuters, 5/23).

28 May 2008

Despondent nurse practitioners - disabling postmodern punishment

The essence of postmodernism theme is that of an epochal shift, discontinuity, or rupture with modernity, bringing new social conditions and sociological principles with it (Baudrillard, 1988). Postmodernism views that the authority and status of the medical professionals does not exist anymore in the area of health care consistent with the postmodern message about the deconstruction of traditional centers of postindustrial authority (Cockerham et.al, 1997).

19 May 2008

U.S. Patent Office allows another significant VNUS patent

VNUS Medical Technologies, Inc. today announced that the U.S. Patent & Trademark Office has decided to allow a second continuation patent application related to the patents in the VNUS patent infringement lawsuit against suppliers of endovenous laser products. This comes on the heels of the Patent Office's decision last month to allow VNUS a separate patent application, also filed as a continuation of one of the patents in the lawsuit.

9 May 2008

Economic downturn prompts many nurses to work more shifts, helps address nursing shortage

The Wall Street Journal on Wednesday examined how the "ailing economy" has prompted many nurses to work additional shifts, delay retirement or return to the work force from retirement -- all of which have helped "ease the nursing shortage."

7 May 2008